University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.
Passage Bio, a US-based genetic therapy developer linked to University of Pennsylvania, filed for a $125m initial public offering yesterday that would enable subsidiaries of conglomerate Access Industries and pharmaceutical firm Eli Lilly to exit.
Passage Bio is working on genetic medicines for life-threatening central nervous system (CNS) disorders with no approved treatments. The filing comes days after it appointed Bruce Goldsmith as chief executive, replacing co-founder and interim CEO Stephen Squinto.
The company has a research,…
